Pain-Identifying and Commercializing Market:First-in-Class Innovation

1
Frontier Pharma Pain-Identifying and
Commercializing Market (First-in-Class
Innovation)
2
Summary

• Large and Innovative Pipeline
• The active pain pipeline is populated by 796
  products across all stages of development, which
  exhibit a highly diverse range of molecular
  targets. GBI Researchs analyses identified 122
  first-in-class programs in active development,
  constituting 13.6 of the pipeline and acting on
  65 first-in-class molecular targets, indicating a
  high degree of innovation.
• Despite being mostly distributed in the early
  stages of development, first-in-class innovation
  is particularly concentrated on novel molecular
  targets that are aligned to the central
  sensitization associated with neuropathic pain,
  which is arguably the most debilitating and
  difficult-to-treat type of chronic pain. This
  gives them the potential to transform the future
  market by expanding the range of drug classes.
• Read The Full Report On http//www.bigmarketrese
  arch.com/frontier-pharma-pain-identifying-and-comm
  ercializing-first-in-class-innovation-market

3
Report Description

• This is in stark contrast to the pain
  therapeutics market, which has been largely
  characterized by only incremental product
  innovation over the last decade, as most market
  segments continue to be dominated by
  long-established active pharmaceutical
  ingredients and the concomitant mechanisms of
  action. Moderate-to-severe pain continues to be
  dominated by opioids that are increasingly being
  reformulated to offer abuse-resistance, while
  mild pain is effectively treated with
  Non-Steroidal Anti-Inflammatory Drugs (NSAID).
• However, significant unmet needs remain, as
  chronic pain and some neuropathic pain subtypes
  do not respond well to existing therapies, which
  are not adequate to treat associated
  hypersensitization and do not align to the
  underlying molecular pathophysiological
  profile.Encouragingly, these first-in-class
  compounds often target molecules which are
  strongly implicated in pain and its associated
  signaling pathways. Although there are
  significant differentiations in the scientific
  rationale and clinical prospects across these
  first-in-class products, the majority demonstrate
  significant Preclinical evidence and alignment to
  molecular pathophysiological changes

4
Key Segment
Highly Diversified Range of Innovative Programs
in Early Pipeline and in Granted Patents Pain is
a complex and multifaceted disorder with a
complex interplay between different pathological
processes, and different pain subtypes exhibit
distinct underlying etiologies and
pathophysiologies. While technological advances
and extensive research efforts have furthered the
understanding of these complex underpinnings,
gaps remain. However, these insights have
translated into the expanding pool of novel
therapeutic targets, as reflected by the highly
innovative pipeline. GBI Researchs proprietary
analysis shows that early-stage, first-in-class
programs exhibit a higher level of diversity with
respect to novel therapeutic targets. The
significant diversity in terms of targets is a
reflection of the complex underpinnings of
distinct pain subtypes. Although the pipeline
continues to feature established therapies, the
range of mechanisms of action employed by novel
compounds is extremely diverse, with the vast
majority residing in the Preclinical stage. This
innovation and diversity is maintained throughout
the pipeline from early- to late-stage
development, although the degree of innovation
diminishes from Phase II. Additionally, although
NSAIDs and opioids remain the cornerstone of pain
treatment, GBI Research analysis indicates a
shift towards pain subtypes that are more
difficult to treat.
5
Key Segment

• In addition, GBI Researchs comprehensive and
  complementary analysis of granted patents
  highlighted a significant number of
  first-in-class product technologies, many of
  which have not been identified in the pain
  product pipelines or even in pipelines across the
  industry. The distribution of these products
  across the molecular target superfamilies and
  families highlighted that they predominantly
  align with the proportional distribution observed
  across the pain pipeline, with G-protein-coupled
  receptors and enzymes inhibitors constituting the
  two major categories. However, an array of novel
  molecular targets within those groups has been
  identified, which do not present in any pipeline
  or marketed products across the industry. A
  significant degree of innovation has also been
  identified in other molecular target categories.
• Active Deals Landscape with Numerous Investment
  Opportunities
• The pain deals landscape has been highly active
  over the past eight years, with 261 licensing
  deals and 112 co-development deals. However,
  despite high levels of investment activity, deals
  for first-in-class products have been relatively
  rare.

6
Key Market

• Overall, more than 50 of deals involving
  first-in-class targets were settled in the early
  stages of development, which is a striking
  contrast with non-first-in-class products, which
  are more frequently entered into deals in the
  later stages of development. This reflects
  companies willingness to invest despite the
  high-risk profile of first-in-class products.
• With 107 first-in-class products available for
  strategic consolidations, a wide variety of
  investment opportunities are available for
  licensing deals or co-development deals in pain.
  This will be encouraged by the growing unmet need
  for chronic pain therapies, and an increased
  understanding of the distinct underlying
  pathophysiologies of distinct pain sub-types,
  allowed by technological advances. Among these,
  some first-in-class products have demonstrated
  promising Preclinical evidence and have
  significant potential to become game-changing
  products, representing high-reward investments.
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/176587

7
SCOPE

• The report covers and includes
• A brief introduction to pain, including the
  different subtypes of pain, pathophysiology, and
  overview of pharmacotherapy and treatment
  algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for pain therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products

8
REASONS TO BUY

• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understand the focal shifts in molecular targets
  in the pain therapeutics pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for pain,
  benchmarked against non-first-in-class targets.
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities

9
Table Of Content

• Executive Summary
• The Case for Innovation
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Pain Patent Analysis
• First-in-Class Target and Pipeline Program
  Evaluation
• Deals and Strategic Consolidations
• Appendix
• Read The Complete TOC _at_ http//www.bigmarketresear
  ch.com/frontier-pharma-pain-identifying-and-commer
  cializing-first-in-class-innovation-market

10
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com